Freeline Therapeutics Holdings Executives
FRLNDelisted Stock | USD 4.31 0.28 6.10% |
Freeline Therapeutics employs about 152 people. The company is managed by 12 executives with a total tenure of roughly 355 years, averaging almost 29.0 years of service per executive, having 12.67 employees per reported executive. Analysis of Freeline Therapeutics' management performance can provide insight into the firm performance.
Freeline |
Freeline Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.555) % which means that it has lost $0.555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0126) %, meaning that it created substantial loss on money invested by shareholders. Freeline Therapeutics' management efficiency ratios could be used to measure how well Freeline Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Freeline Therapeutics Workforce Comparison
Freeline Therapeutics Holdings is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 258. Freeline Therapeutics totals roughly 152 in number of employees claiming about 59% of equities under Health Care industry.
Freeline Therapeutics Notable Stakeholders
A Freeline Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Freeline Therapeutics often face trade-offs trying to please all of them. Freeline Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Freeline Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael JD | CEO Director | Profile | |
Amit MD | Independent Founder | Profile | |
Markus Horer | CTO Founder | Profile | |
Henning Stennicke | Chief Officer | Profile | |
Naomi Aoki | Senior Relations | Profile | |
James Bircher | Chief Officer | Profile | |
Amy Spandau | Interim Finance | Profile | |
Pamela MD | Chief Officer | Profile | |
Arne Naeveke | VP Communications | Profile | |
Alison MD | Sr Officer | Profile | |
Nicole SPHR | Chief Officer | Profile | |
Paul Schneider | Chief Officer | Profile |
About Freeline Therapeutics Management Performance
The success or failure of an entity such as Freeline Therapeutics often depends on how effective the management is. Freeline Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Freeline management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Freeline management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Freeline Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 235 people.
Freeline Therapeutics Workforce Analysis
Traditionally, organizations such as Freeline Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Freeline Therapeutics within its industry.Freeline Therapeutics Manpower Efficiency
Return on Freeline Therapeutics Manpower
Revenue Per Employee | 4.1K | |
Revenue Per Executive | 51.8K | |
Net Loss Per Employee | 328.5K | |
Net Loss Per Executive | 4.2M | |
Working Capital Per Employee | 241.2K | |
Working Capital Per Executive | 3.1M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Transaction History View history of all your transactions and understand their impact on performance |